by | Dec 16, 2019 | Wang, Xiaowei
— Technology Description
In search of more effective cancer treatments, inventors in Dr. Xiaowei Wang’s lab at Washington University School of Medicine have developed artificial interference RNA (aiRNA). aiRNA is a patented chimeric RNAi that combines the multi-target abilities of miRNAs and t…
by | Dec 5, 2019 | Pachynski, Russell
— Disease indication – cancer, particularly lung, breast, colon, and prostate cancer or melanoma (cancers where chemerin is down-regulated at the tumor site)
Drug format – engineered fusion protein
Drug class – first in class
Research stage and Preliminary data
Target &ndash…
by | Dec 1, 2019 | Covey, Douglas, Izumi, Yukitoshi, Zorumski, Charles
— Technology Description
Researchers from Washington University in St. Louis and colleagues have identified ent-allopregnanolone (ent-AlloP) as a potential therapeutic to treat glaucoma. Glaucoma, the leading cause of irreversible blindness, results from damage to the retinal ganglion cells (RGSs) t…
by | Dec 1, 2019 | Caparon, Michael, Flores-Mireles, Ana, Hultgren, Scott, Pinkner, Jerome
— Technology Description
Researchers at Washington University in St. Louis have developed a vaccine strategy to prevent catheter-associated urinary tract infections (CAUTIs). CAUTIs are the most common cause of hospital-acquired infections. Many of these are caused by Enterococcus bacteria. CAUTIs a…
by | Dec 1, 2019 | Hawkins, William, Spitzer, Dirk
— WUSTL Technology 016481
Technology Description
Researchers at Washington University in St. Louis have developed an additional targeting strategy to provide more flexibility and improve the bioactivity of the anticancer therapeutic TR3. This strategy targets TR3 to mesothelin, a tumor biomarker fr…